CClinicalTrials.gg
Sign In
Status unknownNCT05401006Updated Jun 2, 2022

Effect of Acitretin Versus Narrowband Ultraviolet B on Neopterin Level in Psoriatic Patients .

A Phase 4 interventional study of Acitretin 25Mg Cap and Narrowband ultraviolet B in Psoriasis, sponsored by South Valley University. Status unknown at 1 site in Egypt. Open to participants aged 15 Years to 60 Years. Per ClinicalTrials.gov, last updated 2022-06-02.

Sponsored by South Valley University · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2022), so the status shown — last known as Active, not recruiting — may be out of date.

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Jun 2021, registered May 2022).
Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
15 Years to 60 Years
Sex
All
01

Study summary

To evaluate effect of acitretin versus Narrowband UVB on serum level of neopterin in psoriatic patients.

02

Conditions studied

  • Psoriasis

Browse trials for

03

In context

Psoriasis

1,899 studies on the registry are indexed under Psoriasis; 233 are open to participants now.

This study's planned enrollment of 30 is below the median of 70 across 1,447 interventional studies indexed under Psoriasis.

Browse Psoriasis studies →

Lead sponsor

South Valley University is the lead sponsor of 147 studies on the registry; 46 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients with psoriasis diagnosed clinically Aged (15-60).

Exclusion criteria

Exclusion Criteria:

  • Patient with history of skin cancer.
  • Patient with history of photosensitivity.
  • Pregnancy and lactation.
  • Liver failure.
  • Renal failure.
  • Patient with psoriatic artheritis.
  • Patient with allergy to product or any of its components.
  • Patient with poorly controlled dyslipidemia.
  • Patient receiving tetracyclines.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Active comparator
    Acitretin

    Patients will Receive Acitretin (0.25-1 mg /kg/day )for 3months .

    Drug: Acitretin 25Mg Cap

  • Active comparator
    Narrowband ultraviolet B

    Patients will receive Narrowband UVB( 3session /week ) for 3months.

    Radiation: Narrowband ultraviolet B

  • Active comparator
    Combination of Narrowband ultraviolet B and Acitretin

    Patients will receive Acitretin (0.25-1 mg /kg/day ) and Narrowband UVB( 3session /week ) for 3 months.

    Drug: Acitretin 25Mg Cap · Radiation: Narrowband ultraviolet B

Interventions

  • DrugAcitretin 25Mg Cap

    Acitretin is an oral retinoid (a derivative of vitamin A) given in a dose 0.25-1 mg /kg/day for 3months in psoriatic patients

  • RadiationNarrowband ultraviolet B

    Narrowband UVB is the most common form of phototherapy used to treat psoriasis, given 2-3 sessions per week for 3 successive months

    Also known as: Narrowband UVB

06

What researchers measure

Primary outcomes

  1. Serum Neopterin in psoriasis

    Measurement of Neopterin in psoriatic patients before and after treatment with NB-UVB, Acitretin and combination of both modalities using ELISA (enzyme-linked immunosorbent assay).

    Time frame: 3 Months

Secondary outcomes

  1. Treatment of psoriasis

    Clinical evaluation: Assessment of disease severity will be performed by using psoriasis area severity index (PASI score) before and after treatment with NB-UVB, Acitretin and combination of both modalities.

    Time frame: 3 Months

07

Study locations

1 site
  • South Valley University
    Qinā, Egypt
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05401006
Lead sponsor
South Valley University
Responsible party
Fatma Elsayed abd Elfatah Elsayed (Resident doctor, South Valley University) — Principal investigator
First posted
Jun 2, 2022
Start date
Jun 5, 2021
Primary completion
Jun 5, 2022 (estimated)
Completion
Jun 5, 2023 (estimated)
Last update
Jun 2, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Psoriasis→

Other studies from this sponsor

South Valley University

Start the discussion